NCT02640365View on ClinicalTrials.gov

A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

November 18, 2015

Primary Completion Date

December 7, 2016

Study Completion Date

December 7, 2016

Conditions

Unresectable Advanced Cancer

Interventions

DRUG

MM-398

unresectable Advanced non-colorectal cancer

DRUG

Irinotecan

unresectable metastatic colorectal cancer

DRUG

Leucovorin (LV)

unresectable metastatic colorectal cancer

DRUG

5-fluorouracile (5-FU)

unresectable metastatic colorectal cancer

DRUG

bevacizumab

unresectable metastatic colorectal cancer

DRUG

MM-398

unresectable metastatic colorectal cancer

Trial Locations (1)

75012

Hôpital Saint Antoine, Paris

Sponsors

Collaborators (1)

Merrimack Pharmaceuticals

All Listed Sponsors

collaborator

Merrimack Pharmaceuticals

INDUSTRY

lead

GERCOR - Multidisciplinary Oncology Cooperative Group

OTHER

NCT02640365 - A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer | Biotech Hunter | Biotech Hunter